|
Proliferation of tumour cell lines treated with PSK |
||||||
| Cell No. (× 104) |
% inhibition |
|||||
|
|
|
|||||
| Tumour cell line |
Initial |
Control |
PSK1* |
PSK2* |
PSK1 |
PSK2 |
|
|
||||||
| B16 |
25 |
220 ± 5 |
100 ± 2 |
92 ± 2 |
62 |
65 |
| AGS |
14 |
40 ± 1 |
18 ± 1 |
21 ± 1 |
84 |
71 |
| Hela |
25 |
180 ± 5 |
108 ± 4 |
91 ± 4 |
46 |
57 |
| A549 |
25 |
260 ± 5 |
72 ± 2 |
104 ± 3 |
80 |
56 |
| Jurkat |
80 |
325 ± 5 |
224 ± 3 |
208 ± 3 |
41 |
47 |
| B9 |
20 |
90 ± 4 |
75 ± 3 |
72 ± 3 |
22 |
26 |
| Ando-2 |
15 |
30 ± 1 |
20 ± 1 |
22 ± 1 |
67 |
54 |
|
*PSK1: 100 μg/ml; PSK2: 50 μg/ml. P < 0.001 versus control | ||||||
Jiménez-Medina et al. BMC Cancer 2008 8:78 doi:10.1186/1471-2407-8-78 |
||||||